http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2463022-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6379feda6e2eb9af0653088fc5870448 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00 |
| filingDate | 2011-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a16ee506c7c934fe72364f8f1ab4f69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47b721dfdffbe05168631093d1bb12dd |
| publicationDate | 2012-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2463022-C1 |
| titleOfInvention | Method of treating patients with "dry eye" syndrome |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and deals with treatment of "dry eye" syndrome. Method includes obturation of respective lachrymal duct. For this purpose into lower lachrymal duct on 1/3-1/2 of its depth introduced is medication based on stabilised hyaluronic acid in dose 0.2-0.4 ml. Introduction can be performed by means of syringe, provided with metal blunt pointed cannula with internal diameter 1 m, 1 cm long, curved in the middle at 45 degrees. As medication based on hyaluronic acid, mainly Restilane (Restilane Sab-Q) is used. n EFFECT: method makes it possible to obdurate lachrymal ducts in efficient, dosed and atraumatic way with simplification and price reduction of treatment. n 3 cl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2712394-C1 |
| priorityDate | 2011-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.